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Abstract 
Background: Current clinical experience with cellular cardiomyoplasty (using serum bovine-cultivated myoblasts) has demonstrated 
significant malignant ventricular arrhythmias nd sudden deaths in patients. In some ongoing clinical trials the implantation of cardioverter- 
defibrillator is mandatory. We have hypothesized that contact of human cells with fetal bovine serum results after 3-week fixation of animal 
proteins on the cell surface, representing an antigenic substrate for immunological nd inflammatory adverse vents. 
Methods and Results: Autologous myoblasts were transplanted into infarcted LV in 20 patients (90% males, mean age 62±8 years). 
Cells were cultivated in a complete human medium during 3 weeks, using the patients' own serum obtained from a blood sample or from 
plasmapheresis. Injections were performed uring CABG (2.1 grafts/pt). 
All patients had an uneventful recovery. At a mean follow-up of 14±5 months without mortality, no malignant cardiac arrhythmias are 
reported. LV ejection fraction improved from 28±3% to 52:k4.7% (p = 0.03), and regional wall motion score index (WMSI) from 3.1 to 
1.4 (p = 0.04) in the cell-treated segments. Myocardial viability tests showed areas of regeneration. Patients moved from mean NYHA 
class 2.5 to class 1.2. 
Conclusions: A total autologous cell culture procedure was used in cellular cardiomyoplasty reducing the risk of arrhythmia. 
Human-autologous-serum cell expansion avoids the risk of prion, viral or zoonoses contamination. Since patients treated with non- 
cultivated bone marrow cells are free of arrhythmia, the bovine-culture medium seems to be responsible for this complication. Cellular 
cardiomyoplasty may be efficient o avoid progression of ventricular remodeling and subsequent heart failure in ischemic heart disease. 
© 2004 PuNished by Elsevier B.V. All rights reserved. 
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1. Introduct ion 
Cell-based myocardial regenerative therapy (i.e. cellular 
cardiomyoplasty) is undergoing experimental and clinical 
trials in order to limit the consequences of decreased 
contractile fimction and compliance of damaged ventricles 
following myocardial infarction. This biological approach is 
particularly attractive due to the potential for myocardial 
regeneration with a variety of myogenic and angiogenic 
cell types: skeletal myoblasts, bone-marrow-derived mes- 
enchymal stem cells, circulating blood-derived progenitor 
cells, smooth muscle cells, vascular endothelial cells, and 
embryonic stem cells [1-5]. Cellular cardiomyoplasty using 
autologous keletal myoblasts or bone marrow cells has been 
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performed worldwide in more than 200 patients. Inclusion 
criteria consist of adult patients with a low ejection fraction, 
akinetic, non-viable post-infarction scar. 
Current clinical experience with cellular cardiomyoplasty 
(using serum bovine-cultivated myoblasts) has demonstrated 
significant malignant ventricular arrhythmias and sudden 
deaths in patients. In some ongoing clinical trials the 
implantation of cardioverter-defibrillator is becoming manda- 
tory [6-7]. Since patients treated with non-cultivated bone 
marrow cells are free of arrhythmia, we have hypothesized 
that contact of human cells with fetal bovine serum results 
after 3 weeks in fixation of animal proteins on the cell sur- 
face, representing an antigenic substrate for immunological 
and inflammatory adverse vents. At Duke University (USA), 
in a rabbit infarct model treated with autologous myoblast 
transplantation, erratic and aggressive ventricular ectopy and 
lethal bradycardia were observed after cell implantation; the 
cells had been cultivated in horse serum [8]. In an attempt to 
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repair damaged heart muscle and to improve cardiac function, 
we have transplanted autologous muscle cells (myoblasts 
cultivated in autologous human serum) directly into infarcted 
left ventricular areas in 20 cases. 
2. Clinical study 
2.1. Patients 
Since December 2001, cellular cardiomyoplasty procedures 
have been performed in 20 patients (90% males), mean age 
624-8 years. Patients were in mean NYHA FC 2.5 presenting 
with impaired LV function (mean radionuclide jection 
fraction 28-t-3%), LV wall post-ischemic s ars (akinetic and 
metabolically nonviable), and surgical indication for CABG 
in remote, viable and ischemic areas. The procedure was 
approved by the institutional review board, and informed 
written consent was obtained from each patient before the 
procedure. 
2.2. Muscle biopsy and cell culture techniques 
Before initiating the ex-vivo cell culture procedures, the 
following "virus free tests" have been performed: anti human 
immunodeficiency virus (HIV), anti hepatitis B and C virus 
(HBV, HCV), IgM anti cytomegalovirus (CMV), HbsAG, and 
human T-cell leukemiavirus. 
Skeletal muscle biopsy 
Three weeks prior to cellular cardiomyoplasty procedure, 
a biopsy sample of the thigh vastus lateralis was taken 
through a 5-cm incision under local anesthesia. A 2-3 cm 3 
skeletal muscle sample (8-15 g) was explanted under sterile 
conditions. Immediate fragmentation of the muscle with 
scissors was performed and the sample was immerged in 
complete culture medium or in PBS (phosphate buffer 
solution, GIBCO) and kept at 4°C. 
Cell isolation and in vitro expansion 
All manipulations were performed in a laminar flow hood 
using an aseptic technique. The explanted skeletal muscle 
pieces were washed in PBS. Adipose tissue and fascia 
were removed and the muscle was carefully minced with 
scissors. The muscle fragments were washed again in PBS 
until the supernatant remained clear. Tissue dissociation was 
obtained by two consecutive nzymatic treatments: first, 
cells were incubated with collagenase IA (1.5mg/ml/gram 
of tissue) (Sigma Chemical Co) and left in the incubator 
for 1 hour, followed by mechanical dissociation obtained by 
shaking the tube every ten minutes. A second incubation 
with 0.25% trypsin lx EDTA (2 ml, GIBCO BRL) was then 
performed for 20 minutes. Cells were then washed (10 min- 
utes at 300g) and enzymatic reaction stopped by adding 
1 ml of the patient's own serum. Filtration through a 40 ~tm 
sieve (Falcon cell strainer nylon, Becton Dickinson, Franklin 
Lakes, NJ) was then performed and a second enzymatic 
digestion was conducted on the remaining fragments which 
eventually rest on the sieve. 
Cell pellets were resuspended in fresh complete cul- 
ture medium: 79% HAM-F12 medium, 1% penicillin/ 
streptomycin (GIBCO) and 20% patient's erum obtained 
from blood sample (6 patients) or from plasmapheresis 
(14 patients). This plasma exchange procedure was per- 
formed the day before the muscle biopsy using heparin 
as anticoagulant, coagulation proteins were then eliminated 
by neutralization of heparin with protamine sulphate. The 
mean volume of autologous serum obtained for cell cultures 
was 1450-4-220 ml. After testing for bacterial contamination, 
aliquots of 50 ml were cryopreserved until usage. 
The cells were plated in culture flasks and incubated during 
3 weeks at 37°C in a humidified atmosphere containing 
5% CO 2. After a 2-3 day incubation time, the medium 
was changed, eliminating dead cells and blood cells in 
the supernatant, then fresh complete culture medium was 
added. Passaging of the cultures (1:5 split) was carried out 
at subconfluency (50% of conftuency) to avoid myotube 
formation. Cells were harvested by trypsinization (2 ml of 
0.25% trypsin-EDTA in each flask for 1 to 5 minutes in the 
incubator). 
Fibroblast removal from myoblast culture 
Cells underwent a pre-plating step on the first passage to 
deplete fibroblast from the culture. Pre-plating isbased on the 
quicker attachment of fibroblasts compared to myoblasts. On 
the day of transplantation, cells were harvested and washed 
in the injection medium (human albumin 0.5% + complete 
culture medium) and kept in ice before implantation. 
A sample was performed to assess final myoblast rate, by 
flow cytometry test: percentage of myoblasts CD56-positive 
(Miltenyi Biotec, Germany), and desmin antibody positive 
cells (Sigma-Aldrich, France). Cell concentration and via- 
bility were determined with Trypan blue using a Malassez 
cytometer or FACS (flow cytometry). Sterility of cell culture 
was also assessed before implantation (Gram tests). At the 
moment of implantation, the rate of myoblasts was 78-4-5% 
and the rate of viable cells was 95±3%. Density of implanted 
cells was 50-70 million cells per ml. 
2.3. CABG and cellular cardiomyopIasty 
Cells were in-vitro expanded in 17-4-4 days up to 300±20 
millions. Injections were performed uring CABG surgery 
via sternotomy (2.1 grafts/pt). Six procedures were performed 
off-pump and 14 under cardiopulmonary b pass. At the 
end of CABGs, cell implantation was performed into well- 
exposed LV ischemic areas, permitting 12:k3 injection points 
within and principally around the infarct, with a 25Gx40 mm 
retrobulbar ophthalmic needle. Our approach Consisted in 
performing the main implantation i  the peri-infarct area 
(70% of cells), since residual irrigation and collateral 
myocardial revascularization in this intermediate area allows 
for a better survival of the implanted cells. The remaining 
30% of cells were implanted in the central portion of the 
scar. 
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2.4. Postoperative management and clinical follow-up 
All patients received oral amiodarone (200mg/day) as 
antiarrhythmic drug, starting 1 week before surgery and 
up to the third postoperative month. Following surgery the 
patient's cardiac rhythm was monitored with continuous in- 
hospital telemetry. After discharge, ECG-Holter monitoring 
was performed at 1, 2 and 3 months. Ventricular function was 
evaluated by echocardiography (including dobutamine stress 
tests and color kinesis) and radionuclide v ntriculography 
(MIBI gated SPECT). Myocardial viability was assessed with 
fluorodeoxyglucose (18FDG) positron emission tomography 
(PET). 
Dobutamine stress echocardiography 
Pre-implant Post-implant 
6 months 
Fig. 2. Dobutamine stress echocardiography showing improvement i  he 
cell treated LV posterior wall (6-month follow-up). 
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3. Results 
The technique used for "in vitro" cell expansion yielded 
over 300 million cells in 3 weeks, of which more than 70% 
were myoblasts. Cell viability at the moment of injection 
was greater than 90%. All patients had an uneventful 
recovery and discharged from the ICU 3-t-2.2 days fol- 
lowing surgery. Patients were discharged from the hospital 
at 12±3 postoperative days. Patients moved from mean 
heart failure class 2.5 to mean NYHA class 1.2. At a 
mean follow-up of 14±5 months without mortality, no 
malignant cardiac arrhythmias were reported. The mtmber of 
premature ventricular beats/24 hours was 167-4-24 (pre-op), 
28-4-9 (at discharge), 564-13 (at 1 month) and 10±4 (at 
3 months). The postoperative r duction of the number of 
premature ventricular beats could be related to amiodarone 
administration and with surgical revascularization (Fig. 1). 
Radionuclide ventriculography showed improvements of 
LV ejection fraction (from 28±3% to 52±4.7%, p = 0.03). 
Echocardiographic studies of cell-treated segments demon- 
strated improvement in regional wall motion score in- 
dex (WMSI) from 3.1±0.2 to 1.4i0.9 (p=0.04). Dobu- 
tamine stress echoeardiography showed improvement in the 
cell-treated area (Fig. 2). Echocardiography using color- 
kinesis software showed improvement in treated areas 
(Fig. 3). Myocardial viability tests showed areas of regen- 
eration, the mean 18FDG PET increased from pre-operative 
0.158±0.026 to 0.270±0.008~molg -1rain -1 at 3 months 
(p=0.012), the main increased uptake was observed in 
infarcted areas (Fig. 4). 
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Fig. 1. ECG-Holter monitoring following cellular cardiomyoplasty. 
Fig. 3. Echocardiography using color-kinesis software 2 months after 
myoblast implantation, showing LV motion improvement in reated areas. 
[See p. $72 for color illustration.] 
Fig. 4. Myocardial viability test (18FDG PET) showing regeneration of 
infarcted areas (arrow) after cellular cardiomyoplasty (3-month follow-up). 
[See p. $72 for color illustration.] 
The best functional results have been obtained in 6 patients 
presenting a heterogeneous infarct area (patchy appearance), 
i.e. a mixture of viable myocardial tissue and multiple small 
scars. Therefore a "vascularized fibrosis" seems to be a better 
indication for cellular CMP than a "non-vascularized" post- 
infarct scar. 
The association of CABGs with cellular cardiomyoplasty 
was imposed by the institutional review board and thus the 
individual contribution of each procedure cannot be clearly 
elucidated at this stage of our clinical trial. 
4. Discussion 
The goal of cellular cardiomyoplasty is to regenerate 
the myocardium in ischemic and non-ischemic ardiomy- 
opathies. This approach can be performed using surgical 
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or interventional cardiology procedures [9-131. In current 
clinical trials, the number of surgical cell implantations 
seems to be equivalent to those of percutaneous catheter- 
based procedures, and the number of patients treated with 
autologous skeletal myoblasts was equivalent to those treated 
with bone marrow cells. However, there is a tendency to 
use bone marrow cells for myocardial regeneration since this 
approach avoids the 3-week cell culture procedure and the 
risk of ventricular arrhythmias and sudden death observed 
after transplantation of skeletal myoblasts. Directly injecting 
skeletal-myoblasts-derived cells cultivated with bovine serum 
into ischemic myocardium seems to provide a substrate for 
electrical instability, leading to malignant arrhythmia. 
Cellular cardiomyoplasty using autologous myoblasts cul- 
tivated in autologous serum was performed by our group 
in 20 ischemic patients. Techniques for skeletal-myoblasts 
culture and ex-vivo expansion using autologous patient serum 
(obtained from plasmapheresis) have been developed by our 
group. Traditional cell-culture techniques involve the use 
of fetal bovine serum for cell growth. Contact of human 
cells with fetal bovine serum results after 3 weeks in 
fixation of animal proteins on the cell surface, representing 
an antigenic substrate for immunological adverse events. 
After cell implantation an inflammatory reaction may occur, 
creating fibrosis; some human autopsies showed this fibro- 
sis [ 14-171. Malignant ventricular arrhythmias and sudden 
deaths have been reported following serum bovine-cultivated 
cell therapy, and in many cases this complication required 
the implantation of cardioverter-defibrillators. Additional and 
important benefits of human-autologous-serum cell culture 
is that it can be performed without risk of prion, viral or 
zoonose contamination. 
The mechanism by which implanted cells improve heart 
function remains controversial. Cell-based myogenic therapy 
seems to reduce the size and fibrosis of infarct scars, limit 
post-ischemic remodelling, and restore regional myocardial 
contractility in patients following non-massive myocardial 
infarction. Several factors contribute directly or indirectly to 
the structural and functional benefits afforded by muscle-cell 
transplantation. Cells grafted in the infarcted area contribute 
to decrease scar thinning and chamber dilatation (scaffolding 
effect). Muscle-cell implantation increases regional elasticity 
and alters extracellular matrix preventing ventricular re- 
modeling [ 18-211. The regeneration of the collagen matrix 
can be due to the partial reconstitution of the interstitial 
collagen, since during the culture of myoblasts approximately 
20-30% of fibroblasts remain in mixture with muscle cells. 
Following implantation, these fibroblasts could probably con- 
tribute to the regeneration of the myocardial collagen matrix. 
The mechanism explaining the transmission and propagation 
of electromechanical impulses from the native myocardium 
to the engrafted cells has not been elucidated. Response to a 
mechanical stimulus exerted by surrounding cardiomyocytes 
could be responsible for inducing this contraction, since the 
grafted myoblasts are denervated and gap junctions with the 
native myocardium have not been demonstrated [20,22]. 
While various donor cells have been studied to induce 
myogenesis after myocardial infarction, recently interest has 
arisen in promoting cardiac angiogenesis by the transplan- 
tation of vascular endothelial cells or endothelial progenitor 
cells (directly removed or mobilized from bone mar- 
row) [4,5]. This approach retains an important potential as 
an adjunct to myogenic cellular transplantation in inducing 
angiogenesis in injured myocardium, because the mortality 
of muscular cells after implantation in high-fibrotic infarcted 
myocardium seems to be high due to the limited supply 
of oxygen and nutrients within the scar. Thus, cell-based 
angiogenic therapy is in strong development for myocardial 
and limb ischemia due to the instability and adverse response 
to transfection vectors of angiogenic gene therapy, and the 
limitations of growth-factor protein-based therapy, which 
present risks of systemic effects (inducing problematic 
angiogenesis in the retina, intimal arterial hyperplasia with 
development of atheromatous plaque, and potentiation of 
growth and metastasis of occult tumors). 
In conclusion, cell-based myogenic therapy seems to 
reduce the size and fibrosis of infarct scars and to restore 
regional myocardial contractility in patients following non- 
massive myocardial infarction. Current results allow to 
recommend cellular cardiomyoplasty for myocardial regener- 
ation in cases of moderate cardiac insufficiency (i.e., not for 
severe cardiac insufficiency), in order to avoid the progres- 
sion of ventricular remodeling and heart failure. Periodically 
repeated cell-injection procedures could be necessary to 
improve myocardial regeneration and function; this staged 
delivery approach should be facilitated by recently developed 
percutaneous systems, e.g., the “Cell-Fix” catheter-electrode 
for diagnostics and injection in cardiology treatments [23]. 
Autologous serum for cell cultures seems to play a role 
to prevent malignant ventricular arrhythmias and sudden 
death following skeletal myoblast implantation [24-261. New 
experimental and clinical studies should be encouraged. 
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